Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Adverse genetic alterations and their prognostic impact in Chinese b-ALL patients with DUX4 rearrangement

Xiayu Xia, Keyan Yang, Qinlong Zheng Nov 03, 2025 pp. 3367-3367 10.1182/blood-2025-3367

Abstract Background: B-cell acute lymphoblastic leukemia (B-ALL) is a heterogeneous group of hematological malignancy with many molecular sub...

Mim8 improves the In Vivo hemostasis of select hemophilia B causing factor IX variants

Sebastian Leyes Porello, Kyumin Lee, Julia Chau et al. Nov 03, 2025 pp. 4830-4830 10.1182/blood-2025-4830

Abstract Introduction Emicizumab, a first-generation factor VIIIa (FVIIIa)-mimetic, has revolutionized prophylaxis for people with hemophili...

Cdk6 targeting reverses leukemia in germline cebpa Q83X AML mouse model with CMP-origin transformation

Yining Li, Xuan Xiao, Junjin Lin et al. Nov 03, 2025 pp. 985-985 10.1182/blood-2025-985

Abstract CEBPA mutations are frequent drivers of familial AML (FAML) and common in sporadic disease. While bZIP-in-frame mutations (bZIP-if)...

WM-voice: An international discrete choice experiment on treatment preferences in 1,455 patients with Waldenström macroglobulinemia

Anne-Marie Becking, Pythia Nieuwkerk, Michelle Postek et al. Nov 03, 2025 pp. 519-519 10.1182/blood-2025-519

Abstract Introduction: Waldenström macroglobulinemia (WM) is a rare and incurable low-grade non-Hodgkin lymphoma. Therapeutic options are ra...

Real-world outcomes of platelet transfusion in heparin-induced thrombocytopenia: A five-year national study

Areeba Nayyer, Santiago Imhoff, Zeina Assaf et al. Nov 03, 2025 pp. 4880-4880 10.1182/blood-2025-4880

Abstract Background: Heparin-induced thrombocytopenia (HIT) is a prothrombotic, immune-mediated complication of heparin exposure, typically...

Epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Hawaii

Kensuke Takaoka, Manasawee Tanariyakul, Akihiro Miyashita et al. Nov 03, 2025 pp. 7396-7396 10.1182/blood-2025-7396

Abstract Introduction: The epidemiology and clinical characteristics of familial myelodysplastic syndromes/acute myeloid leukemia (MDS/AML)...

Phase 2 trial of cladribine plus immediate rituximab for 1st-line treatment of hairy cell leukemia – long term follow-up of original and additional patient cohorts

Robert Kreitman, Hao-Wei Wang, Dana Delgado Colon et al. Nov 03, 2025 pp. 3609-3609 10.1182/blood-2025-3609

Abstract Background: Hairy cell leukemia is a B-cell malignancy presenting with cytopenias and splenomegaly. It responds well to purine analo...

Long-term safety and effectiveness of systemic bevacizumab for chronic severe bleeding in idiopathic gastrointestinal angiodysplasia, esophageal varices, and angiodysplasia of von willebrand disease and acquired von willebrand syndrome

Nardeen Ayad, Hanny Al-Samkari Nov 03, 2025 pp. 307-307 10.1182/blood-2025-307

Abstract Background Angiodysplasia of the gastrointestinal (GI) tract may be idiopathic or occur secondary to other causes, such as von Will...

Line-of-therapy stratified efficacy of belumosudil in cgvhd : Real-world evidence

Yaogong Wu, Zhaodong Zhong, Jiawen Wang et al. Nov 03, 2025 pp. 7748-7748 10.1182/blood-2025-7748

Abstract Background: In China, belumosudil has been approved for patients failing ≥1 prior therapy, yet dedicated evidence supporting its se...

Race/ethnicity reporting and representation in clinical trials presented at plenary and late-breaking abstract sessions at the American society of hematology (ASH) from 2014 to 2024

Bingtao Xiang, Ryan Nguyen, Ana Maria Avila Rodriguez Nov 03, 2025 pp. 4512-4512 10.1182/blood-2025-4512

Abstract Diversity of clinical trial participants helps ensure generalizability of results to real world patient populations. Despite signif...

Influence of cardiovascular co-morbidities on the in-hospital mortality among patients with sickle cell crisis

Adithya Nagendran, Anushree Venkatesh-Murthy, Muhammad Yousuf et al. Nov 03, 2025 pp. 6223-6223 10.1182/blood-2025-6223

Abstract Background: Sickle cell crisis (SCC) remains a leading cause of emergency hospitalization and acute morbidity i...

Aromatherapy oil during bone marrow biopsy procedure and association with anxiety and pain: An interim analysis

Ali Derakhshani, Jeffrey Li, Aaron Fisher et al. Nov 03, 2025 pp. 2657-2657 10.1182/blood-2025-2657

Abstract Background: Bone marrow aspiration and biopsy (BMAB) is an important procedure for those diagnosed with hematol...

Aberrant thymic architecture and enhanced interferon signaling in down syndrome

Trent Hall, Andrew Schild, Lei Li et al. Nov 03, 2025 pp. 3010-3010 10.1182/blood-2025-3010

Abstract Disrupting the mechanisms of thymocyte development and central tolerance can severely affect the immune system and lead to autoimmu...

Management of a real-world cohort of patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: A multi-institutional analysis

Mark Orland, Praveena Thiagarajan, Serhan Unlu et al. Nov 03, 2025 pp. 1430-1430 10.1182/blood-2025-1430

Abstract Introduction: Iptacopan, the first oral complement inhibitor, offers an attractive alternative to parenteral complement blockers in...

Unveiling FLT3 in B-ALL: Molecular drivers and targeted treatment opportunities

Anna Ferrari, Federico Lo Schiavo, Chiara Salvesi et al. Nov 03, 2025 pp. 5148-5148 10.1182/blood-2025-5148

Abstract Backgroud : The prognosis of B-cell Acute Lymphoblastic Leukemia (B-ALL) patients relapsing after Hematopoietic Stem Cell Transplan...

SLF2 and SMC5 are novel causative genes for inherited bone marrow failure syndromes, driving HSC aging and predisposing to MDS

Sho Shibata, Kazuhisa Chonabayashi, Hirofumi Nakamura et al. Nov 03, 2025 pp. 4989-4989 10.1182/blood-2025-4989

Abstract Although many causative genes have been identified in inherited bone marrow failure syndromes (IBMFS), the genetic etiology remains...

Menin-inhibition boosts CAR-T cell therapy against NPM1 mutated and KMT2A-rearranged acute myeloid leukemia

Johanna Rausch, Philipp Wendel, Viktor Fetsch et al. Nov 03, 2025 pp. 866-866 10.1182/blood-2025-866

Abstract Inhibitors disrupting the Menin-KMT2A chromatin complex have emerged as an auspicious treatment for KMT2A-rearranged (KMT2A-r) leuk...

Results of the Phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy

Justin Watts, Brittany Ragon, Namrata Chandhok et al. Nov 03, 2025 pp. 1650-1650 10.1182/blood-2025-1650

Abstract Background Tumor metabolism is a promising area for drug development in AML. Pegargiminase (ADI-PEG 20), a meta...

Acquired hemophilia a results from a provincial registry highlight the need for improvement of clinical outcomes and bypassing agent use

Nicholas Chornenki, Catherine Lovatt, Andrew Johnston et al. Nov 03, 2025 pp. 3078-3078 10.1182/blood-2025-3078

Abstract Background Acquired Hemophilia A (AHA) is a rare disease with substantial morbidity and mortality. High quality evidence to guide a...

Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center

Alberto Blanco, Andrés Arroyo, Ajai Chari et al. Nov 03, 2025 pp. 2234-2234 10.1182/blood-2025-2234

Abstract Introduction Achieving undetectable measurable residual disease (MRD) is associated with improved progression-f...

Proteomic landscape of histiocytic neoplasms: Advancing precision biomarkers, molecular mechanism, and targeted therapies

Refael Meyuchas, Tamar Ziv, Mali Salmon-Divon et al. Nov 03, 2025 pp. 1211-1211 10.1182/blood-2025-1211

Abstract Introduction Histiocytic neoplasms are rare hematological disorders characterized by clonal proliferation of myeloid-derived cells....

Survival differences in metropolitan versus nonmetropolitan/rural counties in the US: An analysis according to rural-urban continuum codes (RUCC) in the lymphoma epidemiology of outcomes (LEO) study cohort

Mario Ballerini, Melissa Larson, James Foran et al. Nov 03, 2025 pp. 6324-6324 10.1182/blood-2025-6324

Abstract Background: Rural/nonmetropolitan (nonmetro) counties face known barriers to comprehensive cancer care compared with metropolitan (...

Risk-adjusted comparison of survival in chronic myelomonocytic leukemia with and without allogeneic stem cell transplant: Mayo Clinic experience in 775 consecutive patients

Ali Alsugair, Saubia Fathima, Mohammad Alhousani et al. Nov 03, 2025 pp. 5636-5636 10.1182/blood-2025-5636

Abstract Background: The recently published BLAST clinical risk model for chronic myelomonocytic leukemia (CMML) and its molecular version (...

Impact of cancer and therapy on the epigenetic landscapes of normal cells: Describing a novel biomarker in survivorship

Sushil Selvarajan, Uday Kulkarni, Ramachandran Shaji et al. Nov 03, 2025 pp. 1730-1730 10.1182/blood-2025-1730

Abstract Introduction: With the advent of modern multi-drug chemotherapy regimens, several aggressive hematologic malignancies now have exce...

CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial

Xin-di Liu, He-nan Wang, Yuan-zheng Liang et al. Nov 03, 2025 pp. 570-570 10.1182/blood-2025-570

Abstract Background: Chimeric antigen receptor T-cells (CAR-T) targeting CD19 have shown promising benefits to patients of relapsed or refra...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page